Laidlaw Initiates AEON Biopharma Coverage With $1.80 Target

Laidlaw initiated equity research coverage on AEON Biopharma, Inc. with a Buy rating and a price target of $1.80, pointing to upside potential for the clinical-stage biopharmaceutical firm following a steep year-to-date decline.

AEON shares trade at $0.24, having fallen 78% since the beginning of the year and dropping 13% over the prior week of trading. The new coverage arrives as Wall Street firms reassess valuations across micro-cap therapeutics developers amid ongoing broader sector volatility.

Clinical Pipeline and ABP-450 Focus

The investment thesis from Laidlaw centers on the commercial and clinical prospects of AEON's lead therapeutic candidate, ABP-450 (prabotulinumtoxinA). The company is developing the asset as a potential full-label therapeutics botulinum toxin biosimilar designed to compete in therapeutic neurology and dermatology indications.

Initial analytical similarity evaluations for ABP-450 demonstrated that the candidate is structurally identical to benchmark botulinum toxin products, according to company disclosures cited by Investing.com. Demonstrating structural and functional equivalence is a key step for biosimilar developers seeking abbreviated regulatory approval pathways under U.S. Food and Drug Administration guidelines.

Analyst Consensus and Prior Target Revisions

Laidlaw's entry into AEON coverage adds a fresh perspective among sell-side analysts monitoring the micro-cap biopharmaceutical company. Wall Street sentiment remains mixed as smaller drug developers navigate capital-intensive clinical trials against tight financing conditions.

Previously, H.C. Wainwright adjusted its valuation outlook for AEON Biopharma, lowering its price target from $5.00 down to $1.20 while maintaining a Buy rating on the equity. The downward target revisions across coverage providers reflect compressed valuations in the clinical-stage therapeutics space rather than shifts in the core development timeline for ABP-450.

What Is at Stake for AEON Shareholders

For current shareholders, the primary risk remains capital dilution and cash runway management as AEON advances its biosimilar candidate through preclinical and clinical milestones. Micro-cap biotechnology equities trading below $1.00 face heightened regulatory scrutiny from major exchanges regarding minimum bid price requirements, making clinical data readouts and partnership developments critical drivers for ongoing public market listing and liquidity.